CFTR and disease: implications for drug development
- 1 May 2000
- journal article
- Published by Elsevier in The Lancet
- Vol. 355 (9218) , 1840-1842
- https://doi.org/10.1016/s0140-6736(00)02282-0
Abstract
No abstract availableThis publication has 12 references indexed in Scilit:
- Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel functionNature, 1999
- Inhibition of heterologously expressed cystic fibrosis transmembrane conductance regulator Cl− channels by non‐sulphonylurea hypoglycaemic agentsBritish Journal of Pharmacology, 1999
- Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease.American Journal of Kidney Diseases, 1998
- Mutations of the Cystic Fibrosis Gene in Patients with Chronic PancreatitisNew England Journal of Medicine, 1998
- Salmonella typhi uses CFTR to enter intestinal epithelial cellsNature, 1998
- Cloning of the β Cell High-Affinity Sulfonylurea Receptor: a Regulator of Insulin SecretionScience, 1995
- Molecular mechanisms of CFTR chloride channel dysfunction in cystic fibrosisCell, 1993
- Structural model of ATP-binding proteing associated with cystic fibrosis, multidrug resistance and bacterial transportNature, 1990
- Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNAScience, 1989
- Accounting for cystic fibrosisNature, 1988